Skip to main content
SpringerLink
Log in

Erythropoietin in the UK: a setback for gene patents?

  • Patents
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

A decision to invalidate the patent for Amgen's blockbuster is ominous for future gene patents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kirin-Amgen Inc. and others (Appellants) versus Hoechst Marion Roussel Ltd and others (Respondents), House of Lords, 21 October 2004 [2004] UKHL 46 (http://www.parliament.the-stationery-office.co.uk/pa/ld200304/ldjudgmt/jd041021/kirin-1.htm).

  2. Protocol on the Interpretation of EPC Article 69 (footnote to Article).

  3. PC Article 64(2).

Download references

Author information

Author notes

  1. R. Stephen Crespi is a patent attorney based in West Sussex, UK.

    • R Stephen Crespi
Authors
  1. R Stephen Crespi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Crespi, R. Erythropoietin in the UK: a setback for gene patents?. Nat Biotechnol 23, 367–368 (2005). https://doi.org/10.1038/nbt0305-367

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0305-367

  • Springer Nature America, Inc.

Search

Navigation